Chinese expert consensus on the treatment of lymphoma with lenalidomide(2024 edi-tion)
Lenalidomide,a potent immunomodulatory agent,has been demonstrated to have significant efficacy in indolent B-cell lymph-oma treatment.However,its adoption into clinical practice remains a subject of debate for other subtypes of lymphoma,particularly ag-gressive B-cell lymphoma.This controversy stems from the intricate classification of lymphoma subtypes,coupled with disease heterogen-eity from genetic abnormalities and clinical manifestations.To address these challenges,the Lymphoma Committee of China Anti-Cancer As-sociation has developed a comprehensive expert consensus on the clinical utilization of lenalidomide for lymphoma,based on pivotal pro-spective clinical trials and real-world evidences.The consensus comprehensively introduces lenalidomide monotherapy and combination re-gimens,delineating their efficacy across common lymphoma subtypes.Furthermore,it outlines recommendations for administration,dose adjustment in response to adverse effects and special populations,as well as precautions.This expert consensus provides physicians with a robust framework for personalized clinical applications of lenalidomide in the management of lymphoma with safety and effectiveness.
NETL
NSTL
万方数据
